Melanoma Combos Get Mixed Reception From German HTA Body

Germany’s IQWiG says Mekinist plus Tafinlar offers a “considerable” added benefit in melanoma after surgery, but Braftovi plus Mektovi has not shown an additional benefit over comparator therapy in unresectable or metastatic melanoma.

Value dial — The added value of melanoma combinations is under scrutiny in Germany

Novartis’s anticancer combination, trametinib (Mekinist) plus dabrafenib (Tafinlar), offers “considerable added benefit” as adjuvant treatment in adults with stage III melanoma with a BRAF V600 mutation following complete resection of affected tissue, according to the German HTA institute, IqWiG.

IQWiG also assessed another tyrosine kinase inhibitor combination, Pierre Fabre/Array Pharma’s combination of encorafenib (Braftovi) plus binimetinib (Mektovi), which is...